Stock Ratings / Health Care / FEMY / financials

ICU (31) PLSM (47) SINT (33) GUTS (34) ⌘ Pro Terminal →

Femasys Inc. (FEMY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is Femasys Inc. (FEMY)?

In FY 2025 (10-K), FEMY converted $2.3M of revenue into a 62% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$1.36 -3.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.35

Femasys Inc. (FEMY) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $11.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FEMY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FEMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Femasys Inc. (NASDAQ: FEMY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.36 (-3.90% 1D, market cap $11.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, FEMY ranks #863 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FEMY compare to ICU and PLSM in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), FEMY carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 62.0%, and ROIC of -35.0%. By comparison, ICU (SeaStar Medical Holding Corporation) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $12.2M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.5M). Among the 5-stock peer group, FEMY leads on earnings multiple (N/A) while FEMY leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FEMY?

▼

Per FEMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001339005), Femasys Inc. generated $2.3M in revenue (+40.8% YoY), -$18.6M in net income, and -$19.2M in free cash flow against $20.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.35 (-0.89%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FEMY)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY FEMY SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 62% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.75-6.9% Next Q

Q2 (-2Q)

Grade E$1.63-13.5% Next Q

Q3 (-1Q)

Grade E$1.41-3.5% Next Q

Current

Grade E$1.36-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FEMY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FEMY currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.26) and Max Pain ($1.43) forces dealer call-delta covering toward $23.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FEMY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FEMY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How FEMY Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.1M

FY24

Rev $1.6M

FY25

Rev $2.3M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$2.3M	62%	-80%	-$18.6M	-$19.2M	-45%
FY 2024	$1.6M	66.6%	-80%	-$18.8M	-$20.2M	-45%
FY 2023	$1.1M	62%	-80%	-$14.2M	-$11.3M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FEMY)

✓Walkthrough of FEMY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FEMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.72%⚡ TESTING RESISTANCE

2026-11-02O $1.41H $1.41L $1.36C $1.36VOL 110.3K

RES: $2.00SUP: $1.27SMA50: $2.26SMA200: $6.08

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FEMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FEMY Butterfly Map → + Track FEMY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +40.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FEMY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FEMY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FEMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FEMY)

Health Care Rank #863 of 1016 ⚔️ ICU vs FEMY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FEMY vs. ICU, PLSM, SINT, GUTS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Femasys Inc. (FEMY) ranks #863 by composite RQD confidence (30/100, grade E) and #885 by equity capitalization ($11.3M). Within this direct 5-issuer industry benchmark cohort, FEMY leads on earnings valuation at N/A trailing P/E, while FEMY leads on capital efficiency and profitability with -35.0% ROIC and 62.0% gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with FEMY at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FEMY ACTIVE Femasys Inc.	E	30/100	—	62.0%	-35.0%	-3.90%	$11.3M	Benchmark Subject
ICU SeaStar Medical Holding Corporation	E	31/100	—	95.7%	-35.0%	-6.85%	$12.2M	/icu-vs-femy →
PLSM Pulsenmore Ltd.	D	47/100	—	—	—	-8.48%	$10.5M	/plsm-vs-femy →
SINT SiNtx Technologies Inc.	E	33/100	—	45.3%	-35.0%	-1.15%	$13.0M	/sint-vs-femy →
GUTS Fractyl Health Inc.	E	34/100	—	—	-35.0%	+11.40%	$13.2M	/guts-vs-femy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001339005

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Femasys Inc. (FEMY) reported GAAP revenue of $2.3M (+40.8% vs. FY2024 revenue of $1.6M , and +113.9% cumulative change since FY2023) , GAAP net income of -$18.6M, operating cash flow of -$18.7M, and free cash flow of -$19.2M (+4.9% YoY). On the balance sheet, FEMY closed FY2025 with $20.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.3M	-$18.6M	-$18.7M	-$19.2M	$20.7M	—
FY2024 (FY)	2024-12-31	$1.6M	-$18.8M	-$19.4M	-$20.2M	$12.4M	—
FY2023 (FY)	2023-12-31	$1.1M	-$14.2M	-$11.3M	-$11.3M	—	—

3. FEMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FEMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does FEMY compare to ICU and PLSM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for FEMY?

Where is FEMY trading relative to its 50-day, 200-day, and 52-week technical levels?

FEMY last traded at $1.36 (-3.90% on volume of 110,317 shares), positioning the stock -39.82% below its 50-day simple moving average ($2.26) and -77.63% below its 200-day simple moving average ($6.08). Across its 52-week range of $1.30 to $22.20, FEMY sits at the 0.3% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.19 to $1.53).

FEMY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Femasys Inc. (FEMY)?

In FY 2025 (10-K), FEMY converted $2.3M of revenue into a 62% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: FEMY RQD Cockpit FEMY 12M Forecast FEMY Earnings & Move FEMY Dividends & DRIP FEMY Insiders & 13F FEMY Whale Options FEMY Profit Sankey FEMY News & Why